A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted …
The US Sentencing Commission held an open hearing concerning its proposal to increase penalties on MDMA. Testimony about MDMA opposing the increase was presented by Rick Doblin, Ph.D., David Nichols, Ph.D., …
MAPS convened a protocol design meeting in San Francisco to discuss the details of a protocol evaluating the use of MDMA-assisted psychotherapy in the treatment of Post-Traumatic Stress Disorder (PTSD). …
Rick Doblin outlines MAPS’ strategy for the development of the therapeutic use of MDMA into an FDA-approved prescription medicine, at the State of Ecstasy conference in San Francisco, sponsored by …
The first patient was treated in the MAPS-supported MDMA/PTSD study being conducted in Madrid, Spain, under the director of José Carlos Bouso, Ph.D. candidate. José Carlos and Marcela Ot’alora …
A pilot study of MDMA therapy in the treatment of PTSD has been approved and will be the first formal therapy study with MDMA ever conducted. (Read current update) MAPS has pledged $54,000 for this study; …
On September 1, 1999, Jordi Camí, MD, PhD, Magi Farré, MD, PhD, and José Carlos Bouso, PhD presented their Phase 1 clinical study of MDMA-assisted psychotherapy for PTSD at the MAPS MDMA …
MAPS organized an international symposium on the medical utility of MDMA. Talks from this event, held August 31 to September 1, 1999, are posted on this site (talks by George Greer, Juraj and Sonja Styk …
Teleconference with the FDA concerning MDMA psychotherapy research to treat anxiety, depression and pain in cancer patients, the FDA indicates a willingness to approve a “proof of principle” …
